Items where authors include "Race, A.D."

Article

Sun, G., Fuller, H., Fenton, H. et al. (7 more authors) (2025) The relationship between dietary and supplemental n-3 HUFA intake, blood and tissue n-3 HUFA levels, and colorectal polyp recurrence: A secondary analysis of the seAFOod polyp prevention trial. The Journal of Nutrition, 155 (2). pp. 549-558. ISSN 0022-3166

Ingram, N. orcid.org/0000-0001-5274-8502, Abou-Saleh, R.H. orcid.org/0000-0002-8471-2659, Race, A.D. orcid.org/0000-0001-7964-9934 et al. (4 more authors) (2024) Maleimide–Thiol Linkages Alter the Biodistribution of SN38 Therapeutic Microbubbles Compared to Biotin–Avidin While Preserving Parity in Tumoral Drug Delivery. Pharmaceutics, 16 (3). 434. ISSN 1999-4923

Sun, G., Fuller, H., Fenton, H. et al. (7 more authors) (2024) The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial. International Journal of Cancer, 154 (5). pp. 873-885. ISSN 0020-7136

Sun, G., Fuller, H., Fenton, H. et al. (7 more authors) (2024) The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial. International Journal of Cancer, 154 (5). pp. 873-885. ISSN 0020-7136

Sun, G., Davies, J.R. orcid.org/0009-0002-4272-2477, Mell, T. et al. (7 more authors) (2024) APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial. Prostaglandins Leukotrienes and Essential Fatty Acids, 201. 102623. ISSN 0952-3278

Davies, J.R. orcid.org/0009-0002-4272-2477, Mell, T. orcid.org/0009-0001-6744-1340, Fuller, H. orcid.org/0000-0001-8381-519X et al. (10 more authors) (2023) Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial. Cancer Prevention Research, 16 (11). pp. 621-630. ISSN 1940-6207

Davies, J.R. orcid.org/0009-0002-4272-2477, Mell, T. orcid.org/0009-0001-6744-1340, Fuller, H. orcid.org/0000-0001-8381-519X et al. (10 more authors) (2023) Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial. Cancer Prevention Research, 16 (11). pp. 621-630. ISSN 1940-6207

Fuller, H., Race, A.D., Fenton, H. et al. (7 more authors) (2023) Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial. Prostaglandins, Leukotrienes and Essential Fatty Acids, 192. 102570. ISSN 0952-3278

Fuller, H., Race, A.D., Fenton, H. et al. (7 more authors) (2023) Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial. Prostaglandins, Leukotrienes and Essential Fatty Acids, 192. 102570. ISSN 0952-3278

Volpato, M. orcid.org/0000-0002-7851-4533, Ingram, N. orcid.org/0000-0001-5274-8502, Perry, S.L. et al. (8 more authors) (2020) Correction to: Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega‑3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Chemotherapy and Pharmacology, 87 (6). pp. 879-880. ISSN 0344-5704